Related Experiment Video
Updated: Jun 28, 2026
08:43
Recombinant Collagen I Peptide Microcarriers for Cell Expansion and Their Potential Use As Cell Delivery System in a Bioreactor Model
Published on: February 7, 2018
Pluronic F-127 as a cell carrier for bone tissue engineering
Jean-Marc Brunet-Maheu1, Julio C Fernandes, Clemente A V de Lacerda
1Orthopaedic Research Laboratory, Department of Orthopaedics, Centre hospitalier Sacré-Coeur, Montréal, Québec, Canada.
Journal of Biomaterials Applications
|November 7, 2008
Summary
Pluronic F-127 reduces osteoblast viability but preserves their phenotype in vitro. Supplementing with platelet-rich plasma enhances cell survival, suggesting potential for bone tissue engineering applications.
Area of Science:
- Biomaterials Science
- Cell Biology
- Tissue Engineering
Background:
- Osteoblast viability and phenotype maintenance are critical for bone regeneration.
- Pluronic F-127 is a thermoreversible hydrogel with potential biomedical applications.
- Understanding its effect on osteoblasts is essential for tissue engineering.
Purpose of the Study:
- To investigate the impact of Pluronic F-127 on osteoblast (MG-63 cells) viability and phenotype in vitro.
- To assess the influence of platelet-rich plasma on cell survival within the Pluronic F-127 construct.
Main Methods:
- MG-63 cells were cultured in Pluronic F-127.
- Assays included MTT for viability, alkaline phosphatase activity, prostaglandin E2 production, collagen-I, and cyclo-oxygenase-2 expression.
- Experiments were conducted over a 6-day period.
Main Results:
- Pluronic F-127 significantly decreased osteoblast viability over 6 days.
- Osteoblast phenotype remained unaltered despite reduced viability.
- Addition of platelet-rich plasma increased cell survival in the polymer/cell construct.
Conclusions:
- Pluronic F-127 negatively impacts osteoblast viability but does not alter their phenotype.
- Platelet-rich plasma can mitigate the cytotoxic effects of Pluronic F-127 on osteoblasts.
- Pluronic F-127, when combined with bioactive factors, shows promise as a cell carrier for bone tissue engineering.
